Get the SPI Wire

AYTU BIOPHARMA, INC.

NASDAQ:AYTU
Annual Meeting

of Shareholders

MEETING DATE

12/10/2026
DEF 14A FILED
10/22/2026
PUBLISHED
10/22/2026 8:30 pm
TIME TO PUBLISH
10/24/2026
METHODOLOGY
approve
EXCHANGE NASDAQ:AYTU · CUSIP 054754858 · CLASS common stock · CIK 0001385818

RECONCILED · MIXED

Reconciled against the company’s Form 8-K Item 5.07 filed 2026-06-15.

5
FOR
0
AGAINST
0
WITHHOLD
5
BALLOT ITEMS

ITEM-BY-ITEM RECOMMENDATIONS

1
To elect five directors named in the proxy statement to serve until the next annual meeting of stockholders or until their successors are duly elected and qualified
board
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

The Board proposed five current directors for re-election.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
2
To approve Amendment No. 2 to the Aytu BioPharma, Inc. 2023 Equity Incentive Plan
compensation
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

The amendment increases shares reserved under the 2023 Equity Incentive Plan by 500,000 shares.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
3
To approve the Aytu BioPharma, Inc. 2027 Employee Stock Purchase Plan
compensation
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

The filing states the Company does not currently maintain an employee stock purchase plan.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
4
To ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2027
auditor
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Grant Thornton has served as independent auditor since December 12, 2022.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
5
To hold an advisory vote on executive compensation
compensation
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

The Compensation Committee determined fiscal 2026 bonus payouts at 50% of each NEO's target bonus.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.

Ledger

e99f095fbb67e5c478f8b3f9f7056227ecf61c646c7d703b09d3b5a861d767b5

Search company, ticker, executive, director or issue

    The SPI Wire · Proxy Intelligence

    Get every ballot call, before the vote.

    FOR, AGAINST or WITHHOLD on each covered ballot item — published within 48 hours of the definitive proxy filing. Follow the companies you own, or take the full feed.




    Pick the companies you own — you’ll only hear from us on their ballots.

    The SPI Wire covers proxy ballots only — it has nothing to do with Signal Research investigations. Research and analysis for informational purposes; not legal, investment, or voting advice. Unsubscribe anytime.

    Submit Information








      Join Monitoring List




        Receive Research Updates